Hemab Posts Q2 Loss of $24.2M, Gets FDA Nod for Phase 3 Trial
COAG has more than doubled off its 52-week low of $23.
Summary
Hemab reported a Q2 net loss of $24.2 million, or $0.80 per share, alongside $457.5 million in cash. The company also received FDA endorsement to advance to a Phase 3 trial, a major regulatory milestone. This follows the Q1 report that confirmed a cash runway into 2029 and a Breakthrough Therapy designation. The Phase 3 green light materially de-risks the pipeline and could accelerate the path to market. With a market cap near $2.3 billion, the cash position provides ample funding through key clinical readouts.
At the time of this announcement, COAG was trading at $49.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $23.00 to $53.61. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.